Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Centre Georges Francois Leclerc
Primary objective * Main objective of phase I: To evaluate the acute toxicity of treatment with FOLFIRINOX 3 - bevacizumab * Main objective of phase II: To evaluate the efficacy of treatment with FOLFIRINOX 3 - bevacizumab in terms of objective response according to the RECIST criteria. Secondary objectives * To evaluate the efficacy of treatment with FOLFIRINOX 3 - bevacizumab in terms of objective response according to the criteria of CHOI, progression-free survival (PFS) and overall survival (OS) * To evaluate the late toxicity of treatment with FOLFIRINOX 3 - bevacizumab * Evaluate the quality of life
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted